查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800149

全球再生醫學市場：2025年至2030年預測

Global Regenerative Drugs Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2030 年再生醫學市場規模將從 145.4 億美元成長至 290.63 億美元，複合年成長率為 14.86%。

再生醫學是醫療保健領域的創新方法，專注於修復、替換和再生受損的組織和器官，以恢復正常的身體功能。這些藥物透過修復無法自然修復的組織來促進再生，其過程包括再生（將健康細胞和組織輸送到患病或受損部位）和替換（使用捐贈者的健康細胞、組織或器官替代受損組織）。再生醫學的一項關鍵進展是能夠利用患者自身的細胞在實驗室中培育器官，從而有可能降低移植排斥的風險並解決器官短缺的難題。這一創新領域可望徹底改變各醫學學科的治療方法。

市場按類型、材料、應用、最終用戶和地區細分。按類型分類，藥物包括合成藥物、生物衍生藥物和基因衍生藥物，反映了組織修復和再生的多種方法。這些療程中使用的材料包括生物分解性聚合物、支架、水凝膠、膠原膠原蛋白、基因改造材料和纖維母細胞，每種材料均根據特定的再生需求量身定做。應用涵蓋心血管、腫瘤、皮膚、肌肉骨骼、創傷治療、眼科和神經內科等關鍵領域，凸顯了再生醫學的廣泛治療潛力。最終用戶包括醫院、生物醫學實驗室和研究中心，推動這些治療方法的創新和應用。

從區域來看，市場細分為北美、南美、歐洲、中東和亞太地區。歐洲，尤其是德國、法國和英國，是再生醫學的主要樞紐，其強大的商業部門專注於細胞療法。這些治療方法通常利用患者自身細胞或來自非親緣捐贈者的異體細胞，以滿足多樣化的臨床需求並推廣個人化醫療。

再生醫學市場競爭激烈，百特國際、史賽克公司、美敦力公司、CryoLife公司和Organogenic公司（Advanced BioHealing）等主要企業引領著產業發展。這些公司透過研發推動創新，專注於開發新型治療方法和可擴展的解決方案，以滿足日益成長的需求。市場成長的動力源於對再生技術投資的不斷增加，以及對慢性和退化性疾病有效治療方案日益成長的需求。

總而言之，在細胞治療方法和器官再生技術的推動下，再生醫學市場預計將大幅擴張。再生醫學在醫療領域的廣泛應用，加上其在歐洲的強勁表現和全球範圍內日益成長的普及，凸顯了其改變醫療保健行業的潛力。隨著主要企業不斷創新和拓展產品組合，再生醫學有望在滿足未滿足的醫療需求和改善患者預後方面發揮關鍵作用。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
  • 競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力來提供策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業來說，都是有益且具有成本效益的。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2020 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（尤其是趨勢）、財務資訊和關鍵發展

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

第5章 全球再生醫學市場（按技術）

  • 介紹
  • 幹細胞療法
  • 基因治療
  • 組織工程
  • 小分子和生技藥品

第6章全球再生醫學藥物市場（按材料）

  • 介紹
  • 生物分解性合成聚合物
  • 鷹架
  • 水凝膠和膠原蛋白
  • 基因改造
  • 纖維母細胞

第7章全球再生醫學藥物市場（按應用）

  • 介紹
  • 心血管系統
  • 腫瘤學
  • 皮膚科
  • 肌肉骨骼
  • 創傷治療
  • 眼科
  • 神經病學
  • 其他

第8章全球再生醫學市場（按最終用戶）

  • 介紹
  • 醫院
  • 生物醫學研究所
  • 研究中心

第9章全球再生醫學市場（按地區）

  • 介紹
  • 北美洲
    • 依技術
    • 按材質
    • 按用途
    • 按最終用戶
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依技術
    • 按材質
    • 按用途
    • 按最終用戶
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 依技術
    • 按材質
    • 按用途
    • 按最終用戶
    • 按國家
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 依技術
    • 按材質
    • 按用途
    • 按最終用戶
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 依技術
    • 按材質
    • 按用途
    • 按最終用戶
    • 按國家
      • 中國
      • 日本
      • 印度
      • 韓國
      • 台灣
      • 其他

第10章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Organogenesis Holdings Inc.
  • MiMedx Group, Inc.
  • Vericel Corporation
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • Stryker Corporation
  • Medtronic plc
  • Baxter International Inc.
  • Orthofix Medical Inc.
  • RTI Surgical

第12章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061611188

The Global Regenerative Drugs Market is expected to grow from USD 14.540 billion to USD 29.063 billion in 2030, at a CAGR of 14.86%.

Regenerative drugs represent a transformative approach in healthcare, focusing on repairing, replacing, or regenerating damaged tissues and organs to restore normal bodily functions. These medicines facilitate rejuvenation by healing tissues that cannot naturally recover, using processes such as regeneration, where healthy cells or tissues are delivered to diseased or damaged areas, or replacement, where healthy cells, tissues, or organs from donors are used to substitute damaged ones. A significant advancement in regenerative medicine is the potential to grow organs in laboratory settings using a patient's own cells, reducing the risk of transplant rejection and addressing organ shortage challenges. This innovative field holds promise for revolutionizing treatment across various medical domains.

The global regenerative drugs market is segmented by type, materials, application, end-users, and geography. By type, the market includes synthetic, biologically derived, and genetically derived drugs, reflecting diverse approaches to tissue repair and regeneration. Materials used in these therapies encompass biodegradable synthetic polymers, scaffolds, hydrogel and collagen, transgenic materials, and fibroblasts, each tailored to specific regenerative needs. Applications span critical areas such as cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others, highlighting the broad therapeutic potential of regenerative drugs. End-users include hospitals, biomedical laboratories, and research centers, which drive innovation and application of these therapies.

Geographically, the market is divided into North America, South America, Europe, the Middle East, and the Asia-Pacific region. Europe, particularly Germany, France, and the UK, serves as a major hub for regenerative medicine, with a strong commercial sector focused on cell-based therapies. These therapies often utilize autologous cells from the patient or allogeneic cells from unrelated donors, catering to diverse clinical needs and advancing personalized medicine.

The regenerative drugs market is highly competitive, with key players such as Baxter International, Stryker Corporation, Medtronic plc, CryoLife, Inc., and Organogenesis, Inc. (Advanced BioHealing) leading the industry. These companies are driving innovation through research and development, focusing on novel therapies and scalable solutions to meet growing demand. The market's growth is fueled by increasing investment in regenerative technologies and a rising need for effective treatments for chronic and degenerative diseases.

In conclusion, the regenerative drugs market is poised for significant expansion, driven by advancements in cell-based therapies and organ regeneration techniques. Its broad applications across medical fields, coupled with a strong presence in Europe and growing global adoption, underscore its potential to transform healthcare. As key players continue to innovate and expand their portfolios, regenerative medicines will play a pivotal role in addressing unmet medical needs and improving patient outcomes.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Technology

  • Stem cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecules & Biologics

By Materials

  • Biodegradable Synthetic Polymers
  • Scaffold
  • Hydrogel & Collagen
  • Transgenic
  • Fibroblasts

By Applications

  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Neurology
  • Others

By End-Users

  • Hospitals
  • Biomedical Laboratories
  • Research Centers

By Geography

  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL REGENERATIVE DRUGS MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Stem cell Therapy
  • 5.3. Gene Therapy
  • 5.4. Tissue Engineering
  • 5.5. Small Molecules & Biologics

6. GLOBAL REGENERATIVE DRUGS MARKET BY MATERIALS

  • 6.1. Introduction
  • 6.2. Biodegradable Synthetic Polymers
  • 6.3. Scaffold
  • 6.4. Hydrogel & Collagen
  • 6.5. Transgenic
  • 6.6. Fibroblasts

7. GLOBAL REGENERATIVE DRUGS MARKET BY APPLICATIONS

  • 7.1. Introduction
  • 7.2. Cardiovascular
  • 7.3. Oncology
  • 7.4. Dermatology
  • 7.5. Musculoskeletal
  • 7.6. Wound Healing
  • 7.7. Ophthalmology
  • 7.8. Neurology
  • 7.9. Others

8. GLOBAL REGENERATIVE DRUGS MARKET BY END-USERS

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Biomedical Laboratories
  • 8.4. Research Centers

9. GLOBAL REGENERATIVE DRUGS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Technology
    • 9.2.2. By Materials
    • 9.2.3. By Applications
    • 9.2.4. By End-Users
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Technology
    • 9.3.2. By Materials
    • 9.3.3. By Applications
    • 9.3.4. By End-Users
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Technology
    • 9.4.2. By Materials
    • 9.4.3. By Applications
    • 9.4.4. By End-Users
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Technology
    • 9.5.2. By Materials
    • 9.5.3. By Applications
    • 9.5.4. By End-Users
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Technology
    • 9.6.2. By Materials
    • 9.6.3. By Applications
    • 9.6.4. By End-Users
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Organogenesis Holdings Inc.
  • 11.2. MiMedx Group, Inc.
  • 11.3. Vericel Corporation
  • 11.4. Smith & Nephew plc
  • 11.5. Integra LifeSciences Holdings Corporation
  • 11.6. Stryker Corporation
  • 11.7. Medtronic plc
  • 11.8. Baxter International Inc.
  • 11.9. Orthofix Medical Inc.
  • 11.10. RTI Surgical

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations